Remove Article Remove Pharmaceuticals Remove Pharmacy
article thumbnail

India’s Growing Importance in Generic Drug API Manufacturing

Drug Patent Watch

India has long been recognized as a significant player in the global pharmaceutical industry, particularly in the production of generic drugs. The country’s pharmaceutical sector has experienced substantial growth over the years, driven by both domestic and international demand for affordable and high-quality medicines.

article thumbnail

White Bagging Update: PBMs’ Specialty Pharmacies Keep Gaining on Buy-and-Bill Oncology Channels

Drug Channels

specialty pharmacies—via white, brown, and clear bagging—continue to displace buy-and-bill distribution channels for provider-administered oncology drugs. The battle for the specialty patient pits hospitals against insurers—and their respective specialty pharmacies. FYI: The material in today’s article is adapted from Section 3.1.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

The 92-Day Pill Puzzle: Why Your 3-Month Supply Doesn’t Add Up

Drug Patent Watch

Have you ever found yourself scratching your head at the pharmacy counter, wondering why your “3-month supply” of medication doesn’t quite match up with the calendar? You’re not alone.

Pharmacy 108
article thumbnail

White Bagging Update 2022: Hospitals Battle to Boost Buy-and-Bill

Drug Channels

In 2022, specialty pharmacies—via white, brown, and clear bagging—now constitute a meaningful share of the distribution channels for provider-administered oncology drugs. However, buy-and-bill appears to have rebounded substantially at hospitals. Read on for full details and the latest data.

article thumbnail

Four Crucial Questions about the Humira Biosimilar Price War (rerun)

Drug Channels

This week, I’m rerunning some popular posts while I put the finishing touches on our new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. This month, nine biosimilar versions of adalimumab launched in the U.S. No biosimilar has the trifecta of being high-concentration, citrate-free, and fully interchangeable.

article thumbnail

Buprenorphine now replaces methadone as the most common medicine for opioid dependence’: 10-year trends in opioid agonist treatment medicines in Australia

National Drug & Alcohol Research Centre Blog

In Australia, both methadone and buprenorphine have been subsidised by the Pharmaceutical Benefit Scheme (PBS) for the treatment of opioid dependence (termed ‘opioid agonist treatment’ or OAT) for several decades. Our recent article, published in The International Journal of Drugs , presents the Australia-wide results.

Treatment 133
article thumbnail

White Bagging Update 2023: Saving Money or Shifting Costs?

Drug Channels

For 2023, specialty pharmacies—via white, brown, and clear bagging—retained a meaningful share of the distribution channels for provider-administered oncology drugs. Time for our annual update on the channels for provider-administered drugs. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.